BLBC

Brain Liquid Biopsy Consortium

Brain-LBC aims to accelerate research and translation of liquid biopsy approaches for brain tumour patients. The consortium was set up in 2020 and includes leading clinicians and scientists from around the world. Brain-LBC will support sharing of data and of relevant tissue resources with the ultimate aim to identify liquid biopsy techniques that are applicable in real world clinical settings to improve diagnosis and monitoring for brain tumor patients.

About BLBC

The consortium is a group of researchers with an interest in using liquid biopsies to improve treatment experience and outcomes for patients with brain tumours. It brings together scientists and clinicians from all over the globe to pool resources and enable efficient collaboration to bring forward the day when liquid biopsies are used routinely for brain tumour patients. By becoming a member of the consortium, researchers have access to our data base of relevant sample collections in institutions around the world and have the opportunity to interact with leaders in the field. The consortium is also active in education and has strong links to national and international organisations with shared interests

Our Team

Houtan

Houtan Noushmehr

co-founder

Associate Scientist and Director of Liquid Biopsy Program at Henry Ford Health System in Detroit, MI, USA.

Houtan

Houtan Noushmehr

co-founder

Associate Scientist and Director of Liquid Biopsy Program at Henry Ford Health System in Detroit, MI, USA.

Houtan

Houtan Noushmehr

co-founder

Associate Scientist and Director of Liquid Biopsy Program at Henry Ford Health System in Detroit, MI, USA.